Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 21, 2011

Primary Completion Date

October 31, 2016

Study Completion Date

February 10, 2017

Conditions
Metastatic Pancreatic Cancer
Interventions
BIOLOGICAL

GVAX Pancreas

BIOLOGICAL

CRS-207

DRUG

Cyclophosphamide

Trial Locations (10)

10016

NYU Langone Medical Center, New York

10032

Herbert Irving Comprehensive Cancer Center of Columbia University, New York

15213

University of Pittsburgh Medical Center, Pittsburgh

20892

National Cancer Institute, Bethesda

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore

27710

Duke University Medical Center, Durham

33612

H. Lee Moffitt Cancer Center, Tampa

63110

Washington University School of Medicine, St Louis

97213

Providence Portland Medical Center, Portland

98101

Virginia Mason Medical Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Johns Hopkins University

OTHER

lead

Aduro Biotech, Inc.

INDUSTRY

NCT01417000 - Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer | Biotech Hunter | Biotech Hunter